- Malaysia
- /
- Medical Equipment
- /
- KLSE:HARTA
A Look At The Intrinsic Value Of Hartalega Holdings Berhad (KLSE:HARTA)
Key Insights
- Using the 2 Stage Free Cash Flow to Equity, Hartalega Holdings Berhad fair value estimate is RM2.34
- Current share price of RM2.48 suggests Hartalega Holdings Berhad is potentially trading close to its fair value
- Our fair value estimate is 23% lower than Hartalega Holdings Berhad's analyst price target of RM3.02
Today we will run through one way of estimating the intrinsic value of Hartalega Holdings Berhad (KLSE:HARTA) by estimating the company's future cash flows and discounting them to their present value. We will take advantage of the Discounted Cash Flow (DCF) model for this purpose. Models like these may appear beyond the comprehension of a lay person, but they're fairly easy to follow.
We would caution that there are many ways of valuing a company and, like the DCF, each technique has advantages and disadvantages in certain scenarios. If you still have some burning questions about this type of valuation, take a look at the Simply Wall St analysis model.
View our latest analysis for Hartalega Holdings Berhad
The Calculation
We're using the 2-stage growth model, which simply means we take in account two stages of company's growth. In the initial period the company may have a higher growth rate and the second stage is usually assumed to have a stable growth rate. To start off with, we need to estimate the next ten years of cash flows. Where possible we use analyst estimates, but when these aren't available we extrapolate the previous free cash flow (FCF) from the last estimate or reported value. We assume companies with shrinking free cash flow will slow their rate of shrinkage, and that companies with growing free cash flow will see their growth rate slow, over this period. We do this to reflect that growth tends to slow more in the early years than it does in later years.
A DCF is all about the idea that a dollar in the future is less valuable than a dollar today, and so the sum of these future cash flows is then discounted to today's value:
10-year free cash flow (FCF) estimate
2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 | |
Levered FCF (MYR, Millions) | RM144.1m | RM194.4m | RM257.9m | RM452.0m | RM488.0m | RM517.3m | RM544.5m | RM570.4m | RM595.4m | RM620.1m |
Growth Rate Estimate Source | Analyst x4 | Analyst x5 | Analyst x5 | Analyst x1 | Analyst x1 | Est @ 6.00% | Est @ 5.27% | Est @ 4.75% | Est @ 4.39% | Est @ 4.14% |
Present Value (MYR, Millions) Discounted @ 8.7% | RM133 | RM164 | RM201 | RM324 | RM321 | RM313 | RM303 | RM292 | RM281 | RM269 |
("Est" = FCF growth rate estimated by Simply Wall St)
Present Value of 10-year Cash Flow (PVCF) = RM2.6b
The second stage is also known as Terminal Value, this is the business's cash flow after the first stage. For a number of reasons a very conservative growth rate is used that cannot exceed that of a country's GDP growth. In this case we have used the 5-year average of the 10-year government bond yield (3.6%) to estimate future growth. In the same way as with the 10-year 'growth' period, we discount future cash flows to today's value, using a cost of equity of 8.7%.
Terminal Value (TV)= FCF2034 × (1 + g) ÷ (r – g) = RM620m× (1 + 3.6%) ÷ (8.7%– 3.6%) = RM12b
Present Value of Terminal Value (PVTV)= TV / (1 + r)10= RM12b÷ ( 1 + 8.7%)10= RM5.4b
The total value is the sum of cash flows for the next ten years plus the discounted terminal value, which results in the Total Equity Value, which in this case is RM8.0b. The last step is to then divide the equity value by the number of shares outstanding. Relative to the current share price of RM2.5, the company appears around fair value at the time of writing. Valuations are imprecise instruments though, rather like a telescope - move a few degrees and end up in a different galaxy. Do keep this in mind.
The Assumptions
The calculation above is very dependent on two assumptions. The first is the discount rate and the other is the cash flows. Part of investing is coming up with your own evaluation of a company's future performance, so try the calculation yourself and check your own assumptions. The DCF also does not consider the possible cyclicality of an industry, or a company's future capital requirements, so it does not give a full picture of a company's potential performance. Given that we are looking at Hartalega Holdings Berhad as potential shareholders, the cost of equity is used as the discount rate, rather than the cost of capital (or weighted average cost of capital, WACC) which accounts for debt. In this calculation we've used 8.7%, which is based on a levered beta of 0.927. Beta is a measure of a stock's volatility, compared to the market as a whole. We get our beta from the industry average beta of globally comparable companies, with an imposed limit between 0.8 and 2.0, which is a reasonable range for a stable business.
SWOT Analysis for Hartalega Holdings Berhad
- Debt is well covered by earnings.
- Dividend is low compared to the top 25% of dividend payers in the Medical Equipment market.
- Expensive based on P/E ratio and estimated fair value.
- Annual earnings are forecast to grow faster than the Malaysian market.
- Debt is not well covered by operating cash flow.
Next Steps:
Although the valuation of a company is important, it shouldn't be the only metric you look at when researching a company. The DCF model is not a perfect stock valuation tool. Instead the best use for a DCF model is to test certain assumptions and theories to see if they would lead to the company being undervalued or overvalued. If a company grows at a different rate, or if its cost of equity or risk free rate changes sharply, the output can look very different. For Hartalega Holdings Berhad, there are three essential items you should consider:
- Financial Health: Does HARTA have a healthy balance sheet? Take a look at our free balance sheet analysis with six simple checks on key factors like leverage and risk.
- Future Earnings: How does HARTA's growth rate compare to its peers and the wider market? Dig deeper into the analyst consensus number for the upcoming years by interacting with our free analyst growth expectation chart.
- Other Solid Businesses: Low debt, high returns on equity and good past performance are fundamental to a strong business. Why not explore our interactive list of stocks with solid business fundamentals to see if there are other companies you may not have considered!
PS. Simply Wall St updates its DCF calculation for every Malaysian stock every day, so if you want to find the intrinsic value of any other stock just search here.
Valuation is complex, but we're here to simplify it.
Discover if Hartalega Holdings Berhad might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About KLSE:HARTA
Hartalega Holdings Berhad
An investment holding company, engages in the manufacture, retail, and wholesale of latex and nitrile gloves in Malaysia, North America, Europe, rest of Asia, Australia, South America, and the Middle East.
Excellent balance sheet with reasonable growth potential.